Is It Time to Dump Your Shares of Pfizer?

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered ...

Why Pfizer's Headwinds May Already Be In The Price

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

Decoding Pfizer's Options Activity: What's the Big Picture?

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...
The Motley Fool

Can Pfizer's Stock Break This Disappointing Streak?

Shares of the pharmaceutical giant have been in the red for three consecutive years. It just reached a deal with the White House that will give it a three-year grace period on tariffs. Acquisitions ...

Pfizer (PFE): Exploring Valuation as Shares Tick Higher Despite Sector Headwinds

Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand ...